Skip to main content
Premium Trial:

Request an Annual Quote

PGDx's LungSelect

Personal Genome Diagnostics has launched LungSelect, a next-generation sequencing assay that detects a panel of the most common, clinically actionable genetic alterations — including somatic sequence mutations and translocations — in the plasma of non-small cell lung cancer patients. 

The liquid biopsy test is able to detect sequence mutations and translocations at frequencies as low as 0.02 percent and 0.1 percent respectively, with sensitivity greater than 90 percent. The mutations covered are associated with sensitivity or resistance to approved therapies, and could also guide patients to clinical trials of experimental drugs.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more